Nicotine psychopharmacology: Policy and regulatory

Handbook of Experimental Pharmacology

Volumn 192, Issue , 2009, Pages 511-534

  Henningfield, Jack E ^a   Zeller, Mitch ^b  

^a PINNEY ASSOCIATES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM; NICOTINIC AGENT;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CIGARETTE SMOKING; CONTROLLED STUDY; DEATH; DISEASE CONTROL; DRUG DEPENDENCE; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; NEUROPHARMACOLOGY; NONHUMAN; PAIN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUBLIC HEALTH; REVIEW; SMOKELESS TOBACCO; SMOKING; SURGEON; TOBACCO; TOBACCO DEPENDENCE; UNITED STATES; WORLD HEALTH ORGANIZATION; CHEMISTRY; HISTORY; LEGAL ASPECT; PATHOPHYSIOLOGY;

HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NICOTINE; NICOTINIC AGONISTS; SMOKING; TOBACCO; TOBACCO USE DISORDER; TOBACCO, SMOKELESS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 63849319488     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-69248-5_18     Document Type: Review

References (130)

1. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington, DC
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. Revised. American Psychiatric Association, Washington, DC
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
4. Balfour DJ, Fagerstrom KO (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51-81
5. Balster RL (1983) Comments on abuse liability of Nicorette. FDA Drug Abuse Advisory Committee, Rockville, MD
6. Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13-S40
7. Barry H, III (2005) Censorship by a tobacco company. Psychopharmacology 184:273
8. Benowitz NL, Henningfield JE (1994) Establishing a nicotine threshold for addiction. The implications for tobacco regulation. New Engl J Med 331:123-125
9. Benowitz NL, Hall SM, Herning RI, Jacob P, III, Jones RT, Osman AL (1983) Smokers of lowyield cigarettes do not consume less nicotine. New Engl J Med 309:139-142
10. Borland R, Davey C (2004) Impact of smoke-free bans and restrictions. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 707-732
11. Browne CL (1990) The design of cigarettes. Hoechst Celenese Corporation, Charlotte, North Carolina
12. Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995) Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 50:91-96
13. Collins AC, Romm E, Wehner JM (1988) Nicotine tolerance: an analysis of the time course of its development and loss in the rat. Psychopharmacology 96:7-14
14. CorrigallWA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11-20
15. Daynard RA (2004) Roles of tobacco litigation and societal change. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 695-705
16. De Beyer J, Brigden LW (2003) Tobacco control policies: strategies, success, and setbacks. World Bank, Research for International Tobacco Control, Ottawa, CA
17. DeNoble VJ, Mele PC (2005) Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology 184:266-272
18. Djordjevic MV, Hoffman D, Glynn T, Connolly GN (1995) Assessment of nicotine, moisture, and pH. Tob Control 4(1):62-66
19. Domino EF (1999) Pharmacological significance of nicotine. In: Gorrod JW, Jacob P (eds) Analytical determination of nicotine and related compounds and their metabolites. Elsevier, Amsterdam, pp 1-11
20. Drobes D, Klein LC (2004) Research on nicotine and tobacco: a decade of progress. Nicotine Tob Res 6:695-741
21. Fant RV, Henningfield JE, Nelson RA, Pickworth WB (1999) Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 8:387-392
22. Ferno O (1973) A substitute for tobacco smoking. Psychopharmacologia 31:201-204
23. Ferno O (1977) The development of a chewing gum containing nicotine and some comments on the role played by nicotine in the smoking habit. In: Steinfeld J, Griffiths W, Ball K, Taylor RM (eds) Proceedings of the third world conference on smoking and health. US Department of Health, Education, and Welfare, Washington, DC, pp 569-573
24. Finnegan JK, Larson PS, Haag HB (1945) The role of nicotine in the cigarette habit. Science 102:94-96
25. Food and Drug Administration (1995) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed Regist 60:41314-41792
26. Food and Drug Administration (1996) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed Regist 61:44396-45318
27. Goldberg KB (2004) NCI programs: NCI to fund lab testing of "reduced harm" tobacco. Cancer Lett 30:3-5
28. Goldberg SR, Spealman RD, Goldberg DM (1981) Persistent behavior at high rate maintained by intravenous self-administration of nicotine. Science 214:573-575
29. Goldberg SR, Spealman RD, Risner ME, Henningfield JE (1983) Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacol Biochem Behav 19:1011-1020
30. Gray N (2004) Global tobacco control policy. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 659-668
31. Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse. JAI, Greenwich, CT, pp 1-90
32. Griffiths RR, Henningfield JE (1982) Experimental analysis of human cigarette smoking behavior. Fed Proc 41:234-240
33. Gritz ER (1980) Smoking behavior and tobacco use. In: Mello NK (ed) Advances in substance abuse. JAI, Greenwich, CT, pp 91-158
34. Grunberg NE, Popp KA, Bowen DJ, Nespor SM, Winders SE, Eury SE (1988) Effects of chronic nicotine administration on insulin, glucose, epinephrine, and norepinephrine. Life Sci 42: 161-170
35. Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT (1987) Nicotine gum and behavioral treatment: a placebo controlled trial. J Consult Clin Psychol 55:603-605
36. Harris LS (1988) Problems of drug dependence 1987. Proceedings of the 49th annual scientific meeting of the Committee on Problems of Drug Dependence, Philadelphia, June 1987. NIDA
37. Research Monograph no. 81. US Department of Health and Human Services, Rockville, MD
38. Hatsukami DK, Hughes JR, Pickens RW, Svikis D (1984) Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology 84:231-236
39. Henningfield JE (1984) Behavioral pharmacology of cigarette smoking. In: Thompson T, Dews PB, Barrett JE (eds) Advances in behavioral pharmacology, vol 4. Academic, New York, pp 131-210
40. Henningfield JE (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, Accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Third Congress, Second Session. U.S. Government Printing Office, Washington, DC, pp 36-37
41. Henningfield JE (2004) Written direct examination of Jack E. Henningfield, PhD. submitted by the United States pursuant to order #471 Henningfield JE, Goldberg SR (1983) Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19:989-992
42. Henningfield JE, Goldberg SR (1988) Progress in understanding the relationship between the pharmacological effects of nicotine and human tobacco dependence. Pharmacol Biochem Behav 30:217-220
43. Henningfield JE, Hartel CR (1999) Scientific basis for tobacco policy: nicotine research travails. In: GlantzMD, Hartel CR (eds) Drug abuse: origins and interventions. American Psychological Association, Washington, DC, pp 431-446
44. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743-750
45. Henningfield JE, Slade J (1998) Tobacco-dependence medications: public health and regulatory issues. Food Drug Law 53(suppl):75-114
46. Henningfield JE, Woodson PP (1989) Dose-related actions of nicotine on behavior and physiology: Review and implications for replacement therapy for nicotine dependence. J Subst Abuse, 1:301-317
47. Henningfield JE, Zeller M (2002) Could science-based regulation make tobacco products less addictive? Yale J Health Policy Law Ethics III:127-138
48. Henningfield JE, Zeller M (2006) Nicotine psychopharmacology research contributions to United States and global tobacco regulation: A look back and a look forward. Psychopharmacology 184:286-291
49. Henningfield JE, Miyasato K, Jasinski DR (1983) Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 19:887-890
50. Henningfield JE, Miyasato K, Jasinski DR (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1-12
51. Henningfield JE, London ED, Jaffe JH (1987) Nicotine reward: studies of abuse liability and physical dependence potential. In: Engel J, Orleand L (eds) Brain reward systems and abuse. Raven, New York, pp 147-164
52. Henningfield JE, Kozlowski LT, Benowitz NL (1994) A proposal to develop meaningful labeling for cigarettes. JAMA 272:312-314
53. Henningfield JE, Radzius A, Cone EJ (1995) Estimation of available nicotine content of six smokeless tobacco products. Tob Control 4(1):57-61
54. Henningfield JE, Keenan RM, Clarke PBS (1996) Nicotine. In: Schuster CR, Kuhar MJ (eds) Handbook of experimental pharmacology. Springer, Berlin, pp 271-214
55. Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD (1998) Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control 7:281-293
56. Henningfield JE, Benowitz NL, Connolly GN, Davis RM, Gray N, Myers ML, Zeller M (2004) Reducing tobacco addiction through tobacco product regulation. Tob Control 13:132-135
57. Henningfield JE, Stolerman IP, Miczek KA (2006) Nicotine psychopharmacology research: Advancing science, public health, and global policy. Psychopharmacology 184:263-265
58. Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML (2002) Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 72: 559-568
59. Houtsmuller EJ, Henningfield JE, Stitzer ML (2003) Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology 167:20-27
60. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatr 43:289-294
61. Hurt RD, Robertson CR (1998) Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota tobacco trial. JAMA 280:1173-1181
62. Jaffe JH, Jarvik ME (1978) Tobacco use and tobacco disorder. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York, pp 1665-1676
63. Jarvik ME (1977) Biological factors underlying the smoking habit. In: JarvikME, Cullen JW, Gritz ER, Vogt TM, West LJ (eds) Research on smoking behavior. NIDA Research Monograph 17.
64. US Department of Health, Education, and Welfare, Washington, DC, pp 122-148
65. Jarvik ME, Cullen JW, Gritz ER, Vogt TM, West LJ (1977) Research on smoking behavior. NIDA
66. Research Monograph 17, DHEW publication no. (ADM) 78-581. US Department of Health, Education and Welfare, Washington, DC
67. Jha P, Ross H, Corrao MA, Chaloupka FJ (2004) Effective interventions to reduce smoking. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 733-748
68. Johnston LM, Glasg MB (1941) Tobacco smoking and nicotine. Lancet 1:867
69. Kessler DA (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, Accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Third Congress, Second Session. US Government Printing Office, Washington, DC, pp 28-43
70. Kessler DA (2001) A question of intent: a great American battle with a deadly industry. Public Affairs, New York
71. Koop CE (2003) Tobacco addiction: accomplishments and challenges in science, health, and policy. Nicotine Tob Res 5:613-619
72. Koop EC (2004) Tobacco: the public health disaster of the twentieth century. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp v-xvii
73. Krasnegor NA (1979a) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, US Department of Health, Education, andWelfare,Washington, DC
74. Krasnegor NA (1979b) The behavioral aspects of smoking. NIDA Research Monograph 26. Public Health Service, US Department of Health, Education, and Welfare, Washington, DC
75. Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33:374-413
76. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Disc 6:746-762
77. Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street, Rochester, VT London ED, Connolly RJ, Szikszay M, Wamsley JK, Dam M (1988) Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci 8:3920-3928
78. Markou A (2008) Neurobiology of nicotine dependence. Phil Trans R Soc B 363:3159-3168
79. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC (1986) Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 30:427-436
80. Mullins B (2004) How Philip Morris, tobacco foes tied the knot. Roll Call, 5 Oct 2004. Available at: http://www.rollcall.com/issues/50 39/news/7035-1.html. Last accessed 30 Oct 2008
81. Myers ML (2002) Could product regulation result in less hazardous tobacco products? Yale J Health Policy Law Ethics III: 139-147
82. National Cancer Institute (1996) The FTC cigarette test method for determining tar, nicotine, and carbon monoxide yields of U.S. Cigarettes. Report of the NCI Expert Committee. Smoking and Tobacco Control Monograph 7. National Institutes of Health, National Cancer Institute, Bethesda, MD
83. National Cancer Institute (2001) Risks associated with smoking cigarettes with low machinemeasured yields. Smoking and Tobacco Control Monograph 13. National Institutes of Health, National Cancer Institute, Bethesda, MD
84. National Institute on Drug Abuse (NIDA) (1984) Drug abuse and drug abuse research. Public Health Service, US Department of Health and Human Services, National Institute on Drug Abuse, Rockville, MD
85. National Institute on Drug Abuse (NIDA) (1987) The Second Triennial Report to Congress From the Secretary, US Department of Health and Human Services. National Institute on Drug Abuse, Rockville, MD
86. Overton DA (1969) Control of T-maze choice by nicotinic, antinicotinic, and antimuscarinic drugs. Proceedings of the 77th Annual American Psychological Association Convention. 4:869-870
87. Palmatier MI, Evans-Martin FF, Hoffman A, Caggiula AR, Chaudhri N, Donny EC, Liu X, Booth S, Gharib M, Craven L, Alan F, Sved AF (2006) Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. Psychopharmacology 184:391-400
88. Perkins KA, DiMarco A, Grobe JE, Scierka A, Stiller RL (1994a) Nicotine discrimination in male and female smokers. Psychopharmacology 116:407-413
89. Perkins KA, Sexton JE, ReynoldsWA, Grobe JE, Fonte C, Stiller RL (1994b) Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol Biochem Behav 47:295-299
90. Pertschuk M (2001) Smoke in their eyes: lessons in movement leadership from the tobacco wars. Vanderbilt University Press, Nashville, TN
91. Pickworth WB, Bunker EB, Henningfield JE (1994) Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 115:9-14
92. Pinney JM (1979) Preface. In: Krasnegor NA (ed) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, Department of Health Education and Welfare, Washington, DC, pp vii-viii
93. Pomerleau OF, Hughes JR (2005) With a little help from its friends: a brief history of the Society for Research on Nicotine and Tobacco. Nicotine Tob Res 6(3):391-395
94. Miczek KA, Stolerman IP, Henningfield JE (eds) (2006) Special issue on nicotine. Psychopharmacology 184(3-4):263-652
95. Roemer R (2004) A brief history of legislation to control the tobacco epidemic. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 677-694
96. Rose JE, Jarvik ME, Rose KD (1984) Transdermal administration of nicotine. Drug Alcohol Depend 13:209-213
97. Rosecrans JA, Kallman MJ, Glennon R (1978) The nicotine cue: an overview. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier/North-Holland Biomedical, Amsterdam, pp 69-81
98. Royal College of Physicians. (2000) Nicotine addiction in Britain: a report of the tobacco advisory group of the Royal College of Physicians. Royal College of Physicians of London, London Russell MAH (1971) Cigarette smoking: natural history of a dependence disorder. Br J Psychol 44:1-16
99. Russell MAH (1979) Tobacco dependence: is nicotine rewarding or aversive? In: Krasnegor NA (ed) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, US Department of Health Education and Welfare, Washington, DC, pp 100-122
100. Russell MAH (1988) Nicotine replacement: the role of blood nicotine levels, their rate of change, and nicotine tolerance. In: Pomerleau OF, Pomerleau CS, Fagerstrom KO, Henningfield JE, Hughes JR (eds) Nicotine replacement: a critical evaluation. Alan R. Liss, New York, pp 63-94
101. Schneider NG, Jarvik ME, Forsythe AB (1984) Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 9:149-156
102. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997) Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130:352-361
103. Schuster CR, Henningfield J (2003) Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 70:S1-S4
104. Schwartz JL (1987) Review and evaluation of smoking cessation methods: the United States and Canada, 1979-1985. NIH Publication no. 87-2940. Public Health Service, National Institutes of Health, US Department of Health and Human Services, Rockville, MD
105. Schwartz RD, Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220:214-216
106. Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50:35-39
107. Shram MJ, Li Z, Lě AD (2008) Age differences in the spontaneous acquisition of nicotine selfadministration in male Wistar and Long-Evans rats. Psychopharmacology, 197:45-58
108. Slade J, Henningfield JE (1998) Tobacco product regulation: context and issues. Food Drug Law J 53(suppl):43-74
109. Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA (1995) Nicotine and addiction. The Brown and Williamson documents. JAMA 274:225-233
110. Spillane J, McAllister WB (2003) Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend 70:S5-S12
111. Stitzer ML, DeWit H (1998) Abuse liability of nicotine. In: Benowitz NL (ed) Nicotine safety and toxicity. Oxford University Press, Oxford, pp 119-131
112. Stolerman IP, Goldfarb T, Fink R, Jarvik ME (1973) Influencing cigarette smoking with nicotine antagonists. Psychopharmacology 28:247-259
113. Stratton K, Shetty P, Wallace R, Bondurant S (eds) (2001) Clearing the smoke: assessing the science base for tobacco harm. National Academy, Washington, DC
114. Talhout R, Opperhuizen A, vanAmsterdam GC (2007) Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol 17:627-636
115. US Department of Health and Human Services (USDHHS) (1984) Why people smoke cigarettes. (PHS) 83-50195. Public Health Service, US Department of Health and Human Services, Rockville, MD, pp. 1-5
116. US Department of Health and Human Services (USDHHS) (1988) The health consequences of smoking: nicotine addiction. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Center for Health Promotion and Education, Office on Smoking and Health, Rockville, MD
117. US Department of Health, Education, andWelfare (USDHHS) (1979) Smoking and health, a report of the Surgeon General. US Department of Health, Education, and Welfare, Washington, DC
118. Vagg R, Chapman S (2005) Nicotine analogues: a review of tobacco industry research interests. Addiction 100:701-712
119. Warner KE, Slade J, Sweanor DT (1997) The emerging market for long-term nicotine maintenance. JAMA 278:1087-1092
120. Warner KE, Peck CC, Woosley RL, Henningfield JE, Slade J (1998) Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J 53(suppl):1-8
121. Wayne GF, Connolly GN, Henningfield JE (2004) Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 6:927-940
122. Wayne GF, Connolly GN, Henningfield JE (2006) Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob Control 15:189-198
123. Wayne FE, Connolly GN, Henningfield JE, Farone WA (2008) Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation. Nicotine Tob Res 10:613-625
124. World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. The International Bank for Reconstruction and Development, The World Bank, Washington, DC
125. World Health Organization (1992) The ICD-10 classification of mental behavioural disorders. World Health Organization, Geneva, Switzerland
126. World Health Organization (1999) Conclusions to the conference on the regulation of tobacco products. World Health Organization, Geneva, Switzerland
127. World Health Organization (2001) Advancing knowledge on regulating tobacco products. World Health Organization, Geneva, Switzerland
128. World Health Organization Study Group on Tobacco Product Regulation (2004) Recommendation: guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing. World Health Organization, Geneva, Switzerland
129. World Health Organization (2004) The scientific basis of tobacco product regulation, Report of a WHO Study Group, WHO Technical Series 945, Geneva, Switzerland
130. World Health Organization (2007) Tobacco free initiative. The scientific basis of tobacco product regulation. Available online at: http://www.who.int/ tobacco/global interaction/tobreg/tsr/en/index.html